AMENDMENTLicense Agreement • July 8th, 2015 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York
This AMENDMENT (this “Agreement”) is made and is effective as of July 7, 2015 (the “Effective Date of Termination”) by and between Immune Pharmaceuticals Inc., a Delaware corporation having its principal office at 430 East 29th Street, Suite 940, New York, New York (“Immune”) and Endo Pharmaceuticals Inc., a Delaware corporation, having its principal office at 1400 Atwater Drive, Malvern, PA 19355, USA (“Endo”) (each of Immune and Endo being a “Party,” and collectively, the “Parties”).
